Carbone Roberta, Botrugno Oronza A, Ronzoni Simona, Insinga Alessandra, Di Croce Luciano, Pelicci Pier Giuseppe, Minucci Saverio
Department of Experimental Oncology, European Institute of Oncology, and Department of Biomolecular Sciences and Biotechnologies, University of Milan, Italy.
Mol Cell Biol. 2006 Feb;26(4):1288-96. doi: 10.1128/MCB.26.4.1288-1296.2006.
Leukemia-associated fusion proteins establish aberrant transcriptional programs, which result in the block of hematopoietic differentiation, a prominent feature of the leukemic phenotype. The dissection of the mechanisms of deregulated transcription by leukemia fusion proteins is therefore critical for the design of tailored antileukemic strategies, aimed at reestablishing the differentiation program of leukemic cells. The acute promyelocytic leukemia (APL)-associated fusion protein PML-retinoic acid receptor (RAR) behaves as an aberrant transcriptional repressor, due to its ability to induce chromatin modifications (histone deacetylation and DNA methylation) and silencing of PML-RAR target genes. Here, we indicate that the ultimate result of PML-RAR action is to impose a heterochromatin-like structure on its target genes, thereby establishing a permanent transcriptional silencing. This effect is mediated by the previously described association of PML-RAR with chromatin-modifying enzymes (histone deacetylases and DNA methyltransferases) and by recruitment of the histone methyltransferase SUV39H1, responsible for trimethylation of lysine 9 of histone H3.
白血病相关融合蛋白会建立异常的转录程序,导致造血分化受阻,这是白血病表型的一个显著特征。因此,剖析白血病融合蛋白导致转录失调的机制对于设计针对性的抗白血病策略至关重要,这些策略旨在重新建立白血病细胞的分化程序。急性早幼粒细胞白血病(APL)相关融合蛋白早幼粒细胞白血病蛋白-维甲酸受体(PML-RAR)表现为异常的转录抑制因子,因为它能够诱导染色质修饰(组蛋白去乙酰化和DNA甲基化)并使PML-RAR靶基因沉默。在此,我们指出PML-RAR作用的最终结果是在其靶基因上施加类似异染色质的结构,从而建立永久性的转录沉默。这种效应是由先前描述的PML-RAR与染色质修饰酶(组蛋白去乙酰化酶和DNA甲基转移酶)的结合以及负责组蛋白H3赖氨酸9三甲基化的组蛋白甲基转移酶SUV39H1的募集介导的。